Post-polio syndrome is not a dysimmune condition
Isabelle Laffont,Claire Duflos,Christophe Hirtz,Karima Bakhti,Anthony Gelis,Claire Palayer,Valérie Macioce,Marion Soler,Fanny Pradalier,Florence Galtier,Alexandre Jentzer,Claire Lozano,Thierry Vincent,Raul J Morales,Isabelle LAFFONT,Claire DUFLOS,Christophe HIRTZ,Karima BAKHTI,Anthony GELIS,Claire PALAYER,Valérie MACIOCE,Marion SOLER,Fanny PRADALIER,Florence GALTIER,Alexandre JENTZER,Claire LOZANO,Thierry VINCENT,Raul J. MORALES
DOI: https://doi.org/10.23736/s1973-9087.23.08158-3
2024-01-01
European Journal of Physical and Rehabilitation Medicine
Abstract:BACKGROUND: Poliomyelitis is a global disabling disease affecting 12-20 million of people. Post poliomyelitis syndrome (PPS) may affect up to 80% of polio survivors: increased muscle weakness, pain, fatigue, functional decline. It relies on aging of an impaired neuro-muscular system with ongoing denervation processes. A late involvement of humoral or cellular pro-inflammatory phenomena is also suspected.AIM: To assess the dysimmune hypothesis of PPS by comparing lymphocyte subpopulations and humoral immune factors between PPS patients and controls.DESIGN: Cross-sectional study.SETTING: Montpellier University Hospital.POPULATION: Forty-seven PPS and 27 healthy controls.METHODS: PPS patients and controls were compared on their lymphocyte subpopulations and humoral immune factors (IL-1β, IL-6, IL-8, IL-17, IL-21, IL-22, IL-23, IFN-γ, TNF-α, GM-CSF, RANTES, MCP1, MIP-3a, IL-10, TGF-β, IL4, IL13). Patients were further compared according to their dominant clinical symptoms. Sample size guaranteed a power >90% for all comparisons.RESULTS: PPS patients and controls were comparable in gender, age and corpulence. Most patients had lower limb motor sequelae (N.=45, 95.7%), a minority had upper limb motor impairment (N.=16, 34.0%). Forty-five were able to walk (94%), 35/45 with technical aids. The median of the two-minute walking test was 110 meters (interquartile range 55; 132). Eighteen (38%) required help in their daily life. Their quality of life was low (SF36). All described an increased muscular weakness, 40 (85%) a general fatigue, and 39 (83%) muscular or joint pain. Blood count, serum electrolytes, T and B lymphocyte subpopulations and cytokines were comparable between patients and controls, except for creatine phospho kinase that was significantly higher in PPS patients. None of these variables differed between the 20/47 patients whose late main symptoms were pain or fatigue, and other patients.CONCLUSIONS: Our results suggest that PPS is not a dysimmune disease.CLINICAL REHABILITATION IMPACT: Our results do not sustain immunotherapy for PPS. Our work suggest that PPS may be mostly linked to physiological age-related phenomena in a disabled neuromuscular condition. Thus, our results emphasize the role of prevention and elimination of aggravating factors to avoid late functional worsening, and the importance of rehabilitation programs that should be adapted to patients' specific conditions.
rehabilitation